Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
28.6M
-
Shares change
-
+2.13M
-
Total reported value, excl. options
-
$813M
-
Value change
-
+$71.8M
-
Put/Call ratio
-
0
-
Number of buys
-
75
-
Number of sells
-
-56
-
Price
-
$28.45
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q1 2018
152 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q1 2018.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.6M shares
of 166M outstanding shares and own 17.26% of the company stock.
Largest 10 shareholders include FMR LLC (5.79M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.87M shares), BlackRock Inc. (2.51M shares), PERCEPTIVE ADVISORS LLC (2.21M shares), VANGUARD GROUP INC (1.46M shares), STATE STREET CORP (1.15M shares), RENAISSANCE TECHNOLOGIES LLC (961K shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (753K shares), MILLENNIUM MANAGEMENT LLC (595K shares), and Invesco Ltd. (474K shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.